Showing results (151-160 of 396) with videos related to

Sort By:
Pageof 40
Nature|November 5, 2013
A melanocyte lineage program confers resistance to MAP kinase pathway inhibitionCory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMelissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Investigational New Drugs|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 studyStergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMBApril A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
Myc-Driven Glycolysis Is a Therapeutic Target in GlioblastomaKensuke Tateishi, A John Iafrate, Quan Ho, et al.
Plos One|March 26, 2013
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingBrijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, et al.
Cancer Chemotherapy and Pharmacology|April 14, 2010
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumorsAnne M Traynor, Maureen Hewitt, Glenn Liu, et al.
Cancer|June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapyDaniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway ActivationVictoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Pageof 40